These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22708602)

  • 1. AMPA receptors as drug targets in neurological disease--advantages, caveats, and future outlook.
    Chang PK; Verbich D; McKinney RA
    Eur J Neurosci; 2012 Jun; 35(12):1908-16. PubMed ID: 22708602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMPA Receptors as Therapeutic Targets for Neurological Disorders.
    Lee K; Goodman L; Fourie C; Schenk S; Leitch B; Montgomery JM
    Adv Protein Chem Struct Biol; 2016; 103():203-61. PubMed ID: 26920691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis.
    Heath PR; Shaw PJ
    Muscle Nerve; 2002 Oct; 26(4):438-58. PubMed ID: 12362409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substance P receptor activation induces downregulation of the AMPA receptor functionality in cortical neurons from a genetic model of Amyotrophic Lateral Sclerosis.
    Caioli S; Curcio L; Pieri M; Antonini A; Marolda R; Severini C; Zona C
    Neurobiol Dis; 2011 Oct; 44(1):92-101. PubMed ID: 21726643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulating excitatory synaptic neurotransmission: potential treatment for neurological disease?
    Yamada KA
    Neurobiol Dis; 1998 Aug; 5(2):67-80. PubMed ID: 9746904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporospatial coupling of networked synaptic activation of AMPA-type glutamate receptor channels and calcium transients in cultured motoneurons.
    Jahn K; Grosskreutz J; Haastert K; Ziegler E; Schlesinger F; Grothe C; Dengler R; Bufler J
    Neuroscience; 2006 Nov; 142(4):1019-29. PubMed ID: 16949760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of AMPA receptors and VEGF in ALS.
    Van Damme P
    Verh K Acad Geneeskd Belg; 2009; 71(4):241-50. PubMed ID: 20084835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMPA receptor regulation mechanisms: future target for safer neuroprotective drugs.
    Jayakar SS; Dikshit M
    Int J Neurosci; 2004 Jun; 114(6):695-734. PubMed ID: 15204061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors.
    Shemer I; Holmgren C; Min R; Fülöp L; Zilberter M; Sousa KM; Farkas T; Härtig W; Penke B; Burnashev N; Tanila H; Zilberter Y; Harkany T
    Eur J Neurosci; 2006 Apr; 23(8):2035-47. PubMed ID: 16630051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in positive allosteric modulators of the AMPA receptor.
    Morrow JA; Maclean JK; Jamieson C
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):571-9. PubMed ID: 17002217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMPA receptors in epilepsy and as targets for antiepileptic drugs.
    Rogawski MA; Donevan SD
    Adv Neurol; 1999; 79():947-63. PubMed ID: 10514878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excitatory amino acid receptors and neurodegeneration.
    Doble A
    Therapie; 1995; 50(4):319-37. PubMed ID: 7482387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMDA and AMPA receptors contribute to the nicotinic cholinergic excitation of CA1 interneurons in the rat hippocampus.
    Alkondon M; Pereira EF; Albuquerque EX
    J Neurophysiol; 2003 Sep; 90(3):1613-25. PubMed ID: 12702709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium dysregulation in amyotrophic lateral sclerosis.
    Grosskreutz J; Van Den Bosch L; Keller BU
    Cell Calcium; 2010 Feb; 47(2):165-74. PubMed ID: 20116097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMPA receptor positive allosteric modulators: a patent review.
    Pirotte B; Francotte P; Goffin E; de Tullio P
    Expert Opin Ther Pat; 2013 May; 23(5):615-28. PubMed ID: 23405869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slow and selective death of spinal motor neurons in vivo by intrathecal infusion of kainic acid: implications for AMPA receptor-mediated excitotoxicity in ALS.
    Sun H; Kawahara Y; Ito K; Kanazawa I; Kwak S
    J Neurochem; 2006 Aug; 98(3):782-91. PubMed ID: 16893420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xenon reduces N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-mediated synaptic transmission in the amygdala.
    Haseneder R; Kratzer S; Kochs E; Eckle VS; Zieglgänsberger W; Rammes G
    Anesthesiology; 2008 Dec; 109(6):998-1006. PubMed ID: 19034096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paraquat inhibits postsynaptic AMPA receptors on dopaminergic neurons in the substantia nigra pars compacta.
    Lee CY; Lee CH; Shih CC; Liou HH
    Biochem Pharmacol; 2008 Oct; 76(9):1155-64. PubMed ID: 18761327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caspase-mediated suppression of glutamate (AMPA) receptor channel activity in hippocampal neurons in response to DNA damage promotes apoptosis and prevents necrosis: implications for neurological side effects of cancer therapy and neurodegenerative disorders.
    Lu C; Fu W; Mattson MP
    Neurobiol Dis; 2001 Apr; 8(2):194-206. PubMed ID: 11300717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of AMPA receptor desensitization and the side effects of a DMSO vehicle on reticulospinal EPSPs and locomotor activity.
    Tsvyetlynska NA; Hill RH; Grillner S
    J Neurophysiol; 2005 Dec; 94(6):3951-60. PubMed ID: 16107533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.